>>Signaling Pathways>> Others>>Anti-neurodegeneration agent 1

Anti-neurodegeneration agent 1

Catalog No.GC31244

항신경변성제 1 특허 WO2008039514A1, 화합물 I에서 추출한 신경변성 표적 화합물.

Products are for research use only. Not for human use. We do not sell to patients.

Anti-neurodegeneration agent 1 Chemical Structure

Cas No.: 289893-23-8

Size 가격 재고 수량
1mg
US$534.00
재고 있음
5mg
US$1,057.00
재고 있음
10mg
US$1,801.00
재고 있음
20mg
US$3,171.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.

In Anti-neurodegeneration agent 1 (Compound I)-treated mSODl(G93A) mice, Western blot analysis reveals an observable 'band shift' of HSF-I, indicative of a stress-induced activation of HSF-I by hyper-phosphorylation. Immunostaining reveals that, at 120 days of age, expression of Hsp70 and Hsp90 is increased in the lumbar spinal cords of both untreated and Anti-neurodegeneration agent 1- treated SOD1(G93A) mice, although there is a clear increase in the intensity of Hsp70 and Hsp90 immunoreactivity in motor neurons of Anti-neurodegeneration agent 1-treated mSODl(G93A) mice. Anti-neurodegeneration agent I- treated mice live an average of 153 days (±2.6 SEM, n=7). This represents a significant increase in lifespan of over 22% (p=

[1]. BARBER, Jack R. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH NEURODEGENERATION. WO2008039514A1.

리뷰

Review for Anti-neurodegeneration agent 1

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Anti-neurodegeneration agent 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.